Vascularization of Human iPSC‐Derived Kidney Organoids Using Perfusion Culture, Pre‐Vascularized Collagen Scaffolds, and Decellularized Extracellular Matrix
Exposure to the calcineurin inhibitor tacrolimus revealed dose‐dependent cytotoxicity and characteristic nephron and vascular injury, demonstrating the model's utility for nephrotoxicity screening and establishing foundations for physiologically relevant models for disease modeling and pre‐clinical drug testing.
Abstract
Human induced pluripotent stem cell‐derived kidney organoids represent promising in vitro models for studying kidney development and drug‐induced toxicity, yet their lack of vasculature limits maturation and translational use. Here, we present a proof‐of‐concept co‐culture platform to promote vascularization of kidney organoids by integrating stromal vascular fraction cells, collagen sponge scaffolds, porcine kidney decellularized extracellular matrix (dECM), and dynamic culture in a perfusion‐based U‐CUP bioreactor. We systematically evaluated the effects of serum supplementation, scaffold pre‐vascularization, dECM encapsulation, and flow conditions on organoid–vascular integration. Low‐level serum supplementation (1.5% FBS) sustained vascular networks without compromising organoid morphology. Perfusion supported vascular expansion; however, while a low flow rate comparable to interstitial tissue flow (0.01 mL/min) preserved organoid morphology and glomerular‐like structures, a higher flow rate optimized for vascularization (0.47 mL/min) disrupted overall organoid architecture. Encapsulation within dECM preserved glomerular morphology and supported vascular infiltration, whereas co‐culture with stromal vascular fraction cells enabled putative podocyte–endothelial interactions. Finally, exposure to the calcineurin inhibitor tacrolimus revealed dose‐dependent cytotoxicity and characteristic nephron and vascular injury, demonstrating the model's utility for nephrotoxicity screening. The established modular platform enables the engineering of vascularized kidney organoids, establishing foundations for physiologically relevant models for disease modeling and pre‐clinical drug testing.
Transplantation of vascular cells is a potential strategy for enhancing vascular regeneration in the treatment of ischemic diseases. However, its therapeutic application is limited by poor engraftment and insufficient vascular integration. Here, we develop a scalable methodology for generating suspensible, homogeneou...
Wei-Jing Kong, Zi-Hang Pan, Yi Hong et al.· Nature Communications· 0 citations
Constructing human vascularized artificial tissues (HVATs) that form stable vascular structures after transplantation remains challenging in regenerative medicine. Using the cryopreserved cell accumulation method (CP-CAM), a scaffold-free approach based on extracellular matrix nanofilm-coated cells, we generated HVAT...
This optimized method enables the scalable production of high-quality vascular organoids suitable for studying vascular cell interactions, modeling disease, and screening compounds, thereby lowering the technical barrier for laboratories seeking to adopt this model system.
Ischemic vascular diseases remain a major clinical challenge, creating a need for engineered vascular tissues that can establish functional vascular networks and promote durable tissue repair. Conventional vascular organoids offer limited control over cellular composition and spatial organization, while the fate and ad...
Xin-Yu S. Fu, Li Yan, Zhao-Sen Chen et al.· BMC Medicine· 0 citations
Small‐diameter vascular grafts (≤ 6 mm) remain a critical unmet need in cardiovascular surgery, as autologous vessels are unavailable in up to 30% of patients requiring coronary or peripheral bypass. Induced pluripotent stem cells (iPSCs) have emerged as a transformative cell source for tissue‐engineered vascular graft...
Dohee Kim, Seohyun Choo, Seung-Hun S. Lee· Journal of Cellular Physiolo...· 0 citations